AMH and breast carcinoma: One article that studied 17 breast cancer or lymphoma patients (aged 19–35 years) showed that their serum AMH levels dropped to a low or undetectable level after 1–2 cycles of multi‐agent chemotherapy, and the median level of AMH for those receiving alkylating agents remained to be lower than 0.05 ng/mL (range 0.05–0.54 ng/mL) 1 year after treatment.21